Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 13/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA4 | P22748 | 1/20 | 0.49 |
| ▸ | CA6 | P23280 | 1/20 | 0.49 |
| ▸ | CA5A | P35218 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.49 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethoxyresorufin SCHEMBL31079400 | 1.00 | APP (1.00) | APPCYP1A2CA12CA1CA4 | |
| SCHEMBL1104922 | 0.90 | APP (0.82) | APPCYP1A2CA12CA1CA4 | |
| SCHEMBL16069679 | 0.90 | APP (0.81) | APPCYP1A2CA12CA1CA4 | |
| SCHEMBL505449 | 0.88 | APP (0.78) | APPCYP1A2CA12CA1CA4 | |
| SCHEMBL31492097 | 0.88 | APP (0.78) | APPCYP1A2CA12CA1CA4 | |
| SCHEMBL1104925 | 0.87 | APP (0.80) | APPCYP1A2CA12CA1CA4 | |
| SCHEMBL10167880 | 0.86 | APP (1.00) | APPCYP1A2 | |
| SCHEMBL10167882 | 0.85 | APP (1.00) | APPCYP1A2 | |
| SCHEMBL563392 | 0.85 | APP (1.00) | APPCYP1A2CA12CA1CA4 | |
| SCHEMBL31115697 | 0.85 | APP (1.00) | APPCYP1A2CA12CA1CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1472 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250093331-A1 | METHOD FOR DETERMINING ACUTE TOXICITY AND A SYSTEM USING SAID METHOD | CITY UNIVERSITY OF HONG KONG (HK) | 2025-03-20 | — | — | US | claimed |
| US-12098391-B2 | Generation of hepatocytes from pluripotent stem cells | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2024-09-24 | — | — | US | claimed |
| CN-107478816-A | Poison test for cosmetic products | 水中银(国际)生物科技有限公司 | 2017-12-15 | — | — | CN | claimed |
| CN-103487412-B | Method for constructing rapid hepatotoxicity predication model of phenolic compound | UNIV SHANGHAI JIAOTONG | 2015-07-15 | — | — | CN | claimed |
| CN-103487412-A | Method for constructing rapid hepatotoxicity predication model of phenolic compound | UNIV SHANGHAI JIAOTONG | 2014-01-01 | — | — | CN | claimed |
| US-20050215533-A1 | Method to inhibit ischemia and reperfusion injury | RADICAL THERAPEUTIX | 2005-09-29 | — | — | US | claimed |
| EP-0649472-B1 | FUSION PROTEINS COMPRISING EUKARYOTIC CYTOCHROME P450 FUSED TO A REDUCTASE | UNIV TEXAS (US) | 2003-12-10 | — | — | EP | claimed |
| EP-1083223-A1 | NOVEL IMMORTALIZED HEPATIC CELL LINE ORIGINATING IN HUMANS | Takeda Chemical Industries, Ltd. (JP) | 2001-03-14 | — | — | EP | claimed |
| EP-0649472-A4 | FUSION PROTEINS COMPRISING EUKARYOTIC CYTOCHROME P450 FUSED TO A REDUCTASE. | UNIV TEXAS (US) | 1997-03-19 | — | — | EP | claimed |
| EP-0649472-A1 | FUSION PROTEINS COMPRISING EUKARYOTIC CYTOCHROME P450 FUSED TO A REDUCTASE | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1995-04-26 | — | — | EP | claimed |
| WO-1994001568-A1 | FUSION PROTEINS COMPRISING EUKARYOTIC CYTOCHROME P450 FUSED TO A REDUCTASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1994-01-20 | — | — | WO | claimed |
| WO-1992013076-A1 | METHODS AND COMPOSITIONS FOR THE EXPRESSION OF BIOLOGICALLY ACTIVE EUKARYOTIC CYTOCHROME P450S IN BACTERIA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1992-08-06 | — | — | WO | claimed |
| US-4865972-A | Antibody-based bioassay for enzyme-inducing chemicals | WESTINGHOUSE ELECTRIC CORP. (US) | 1989-09-12 | — | — | US | claimed |
| EP-0259073-A2 | Antibody-based bioassays for enzyme-inducing chemicals | WESTINGHOUSE ELECTRIC CORPORATION (US) | 1988-03-09 | — | — | EP | claimed |
| US-12606560-B1 | Method of converting mitragynine to 7-hydroxymitragynine | MITCHELL HAYWOOD MAX (US) | 2026-04-21 | — | — | US | disclosed |
| US-20260097037-A1 | FUSED RING COMPOUND HAVING GLP-1 RECEPTOR AGONIST EFFECT | SHIONOGI & CO., LTD. (JP) | 2026-04-09 | — | — | US | disclosed |
| US-20260098031-A1 | MONOCYCLIC COMPOUND HAVING GLP-1 RECEPTOR AGONIST ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2026-04-09 | — | — | US | disclosed |
| EP-0259073-A2 | Antibody-based bioassays for enzyme-inducing chemicals | WESTINGHOUSE ELECTRIC CORPORATION (US) | 1988-03-09 | — | — | EP | disclosed |
| US-4599901-A | Pressure-sensitive optrode | UNIVERSITY OF CALIFORNIA (US) | 1986-07-15 | — | — | US | disclosed |
| EP-0183329-A2 | Pressure-sensitive optrode | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1986-06-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260098031-A1 | MONOCYCLIC COMPOUND HAVING GLP-1 RECEPTOR AGONIST ACTIVITY | GLP1R, GCGR, CCKAR | APP 3917/4885CYP1A2 3925/4885CA12 2495/4885 |
| US-20260097037-A1 | FUSED RING COMPOUND HAVING GLP-1 RECEPTOR AGONIST EFFECT | GLP1R, CCKAR, GCGR | APP 3879/4885CYP1A2 3450/4885CA12 3023/4885 |
| US-12606560-B1 | Method of converting mitragynine to 7-hydroxymitragynine | LIPA, DHCR7, VAMP7 | APP 4783/4885CYP1A2 1373/4885CA12 3348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.